Foster Dykema Cabot & Partners LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 21.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 33,560 shares of the company's stock after selling 9,163 shares during the quarter. Eli Lilly and Company makes up 2.0% of Foster Dykema Cabot & Partners LLC's holdings, making the stock its 16th largest holding. Foster Dykema Cabot & Partners LLC's holdings in Eli Lilly and Company were worth $25,908,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the business. CWA Asset Management Group LLC lifted its position in shares of Eli Lilly and Company by 11.9% in the 4th quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock worth $5,245,000 after purchasing an additional 724 shares during the period. Centerpoint Advisory Group acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $514,000. M&T Bank Corp grew its holdings in shares of Eli Lilly and Company by 0.7% during the third quarter. M&T Bank Corp now owns 266,822 shares of the company's stock valued at $236,389,000 after buying an additional 1,867 shares during the last quarter. Kentucky Trust Co acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $834,000. Finally, Proficio Capital Partners LLC lifted its position in Eli Lilly and Company by 30.2% during the 4th quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock worth $5,202,000 after acquiring an additional 1,562 shares during the period. 82.53% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
LLY has been the subject of a number of research reports. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their target price for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Truist Financial lifted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. StockNews.com raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Morgan Stanley reduced their target price on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating for the company in a report on Wednesday, April 9th. Finally, Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research report on Friday, January 17th. Two research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,012.00.
Read Our Latest Stock Report on LLY
Eli Lilly and Company Price Performance
Shares of NYSE LLY traded up $106.80 during trading on Friday, hitting $841.70. The company had a trading volume of 10,843,294 shares, compared to its average volume of 3,427,703. The firm has a market capitalization of $798.08 billion, a price-to-earnings ratio of 71.88, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The stock has a fifty day simple moving average of $829.09 and a two-hundred day simple moving average of $820.35. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.
Insider Buying and Selling at Eli Lilly and Company
In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.14% of the stock is currently owned by insiders.
About Eli Lilly and Company
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
See Also
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
